Background: Osimertinib is an oral third-generation TKI that targets EGFR T790M mutations in metastatic NSCLC. This study explored model-based meta-analysis PK models for osimertinib by developing a new population PK model based on simulated data. The research aimed to merge existing literature on osimertinib\'s population pharmacokinetics (PK) to formulate a novel population PK model based on simulated data, thereby exploring the validity and utility of a model-based meta-analysis PK model for osimertinib.Methods: From existing population PK studies, we identified 3 studies via PubMed and Google Scholar. A normal distribution was applied for demographic covariates, and literature-sourced PK parameters were incorporated into simulations using Python and which were then used to simulate plasma concentration-time profiles for virtual patients using R version 4.2.2 , mrgsolve package. Results: One-compartment model described the PK of Osimertinib. A significant correlation was found between albumin concentration and body weight, and the pharmacokinetic parameters of volume of distribution (Vd) and clearance (CL). Conclusion:  The aim of this study was to develop a novel population pharmacokinetic model for osimertinib based on meta-analyses and simulations of plasma concentration-time data from virtual patient cohorts. PK of osimertinib is affected by albumin and body weight, therefore, dosage adjustments can be made based on these factors.